Rhumbline Advisers increased its holdings in Revvity, Inc. (NYSE:RVTY - Free Report) by 9.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 223,067 shares of the company's stock after buying an additional 19,543 shares during the period. Rhumbline Advisers owned about 0.19% of Revvity worth $23,600,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. Assetmark Inc. raised its stake in Revvity by 3,700.0% in the fourth quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after buying an additional 259 shares in the last quarter. Optiver Holding B.V. acquired a new position in shares of Revvity during the fourth quarter worth $33,000. Quarry LP increased its position in shares of Revvity by 45.7% during the fourth quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after purchasing an additional 95 shares in the last quarter. Millstone Evans Group LLC acquired a new position in shares of Revvity during the fourth quarter worth $38,000. Finally, Vermillion Wealth Management Inc. acquired a new position in shares of Revvity during the fourth quarter worth $41,000. Institutional investors own 86.65% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on RVTY. The Goldman Sachs Group reduced their price target on Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Wells Fargo & Company reduced their price target on Revvity from $130.00 to $102.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen downgraded Revvity from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Raymond James reaffirmed an "outperform" rating and set a $120.00 price target (down from $145.00) on shares of Revvity in a research report on Tuesday, April 29th. Finally, Barclays reduced their price target on Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $125.64.
View Our Latest Stock Analysis on Revvity
Revvity Stock Performance
NYSE:RVTY traded up $1.49 during mid-day trading on Friday, hitting $91.99. The company's stock had a trading volume of 903,371 shares, compared to its average volume of 955,943. Revvity, Inc. has a 1 year low of $87.70 and a 1 year high of $129.50. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03. The stock has a market cap of $10.84 billion, a price-to-earnings ratio of 41.63, a PEG ratio of 3.82 and a beta of 0.97. The business's fifty day moving average is $93.51 and its two-hundred day moving average is $107.48.
Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings results on Monday, April 28th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.96 by $0.05. The company had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The firm's revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.98 earnings per share. Analysts anticipate that Revvity, Inc. will post 4.94 EPS for the current fiscal year.
Revvity Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be issued a $0.07 dividend. The ex-dividend date is Friday, July 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. Revvity's payout ratio is 11.91%.
Revvity Company Profile
(
Free Report)
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Featured Articles
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
